1. Introduction {#s0005}
===============

Fatty liver diseases are divided into two categories: alcoholic fatty liver disease (AFLD) and nonalcoholic fatty liver disease (NAFLD) ([@b0080]). NAFLD is more common in clinical practice and can seriously impact the quality of a patient's life. The current clinical treatments for NAFLD include insulin sensitization agents, lipids, diet pills, antihypertensive agents, cell protective agents, anti-inflammatory cytokine antioxidants and other types ([@b0070], [@b0030]). In recent years, with improvements of the living standards and the changes of the diet structure of the people, the incidence of NAFLD has increased year by year, but the pathogenesis is not entirely clear. Drug treatment is not perfect; therefore, there is an urgent need for new drugs that can enhance prevention and treatment of NAFLD ([@b0120]).

Chitosan (CTS), a linear biopolymer comprising glucosamine and *N*-acetyl-glucosamine residues, is an *N*-deacetylated product of chitin and one of the most abundant polysaccharides in nature ([@b0065]). CTS is non-toxic, biocompatible, biodegradable and highly soluble in acidic solutions, and it has been widely used in the chemical industry, environmental protection, food, pharmaceutics, medicine, cosmetics, agriculture and many other fields ([@b0065], [@b0095]). However, its high molecular weight has limited its applications. Fortunately, CTS can be hydrolyzed enzymatically by specific chitosanases and non-specific enzymes. The degradation products of CTS, COS, not only can be used as drug carrier ([@b0115], [@b0010]), but also has better biological activity owing to the rise in the water soluble ([@b0005]). COS has also been implicated in many biological activities, such as lowering blood lipids, controlling blood pressure and blood glucose, and producing other antidiabetic actions ([@b0020], [@b0025], [@b0050]). In addition, COS has been also widely used in the field of functional food ([@b0045], [@b0020], [@b0025]). Increasing researchers have devoted themselves to the study on the molecular mechanisms on the various physiological functions of COS and related products aforesaid, especially its anti-obesity and hypolipidemic capacity ([@b0040], [@b0125], [@b0130], [@b0110]). However, there has been very little research on the use of COS for NAFLD; therefore, the goal of this study was to simulate the pathological characteristics of clinical NAFLD. Oleic acid-induction of HepG2 cells leads to a significant increase in lipid droplets. This system can thus be used as a lipid accumulation model. The actions of two types of COS with different molecular weights are evaluated for their efficacy at reducing intracellular lipid accumulation. This study can be used to test their potential value in the prevention and treatment of fatty liver disease.

2. Materials and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

The human hepatocellular carcinoma cell line HepG2 was provided by the Institute of Chinese Medical Science of Guangdong Pharmaceutical University. Drugs and reagents used in this study include the following: Chitooligosaccharides I and II with average molecular weights of 1000 and 3000, Shandong Laizhou Haili Biological Products Co. Ltd., Shangdong, China, GIBCO Dulbecco's Modified Eagle Medium (DMEM), Invitrogen Co. Ltd., New York, American, Fetal bovine serum (FBS), Hyclone Co. Ltd., Utah, American, Trypsin, Amresco Co. Ltd., Ohio, American, Sodium oleate, Tokyo chemical industry Co. Ltd., Tokyo, Japan, Oil red O staining solution, Zhuhai Beisuo Biological Technology Co. Ltd., Guangdong, China, Triglyceride kits, Biosino Biotechnology & Science Inc., Beijing, China, and Thiazolyl blue tetrazolium bromide (MTT), Sigma Co. Ltd., San Francisco, American. All other reagents and solvents were of analytical reagent grade.

2.2. Preparation of drug solution {#s0020}
---------------------------------

Preparation of the induction solution for lipid accumulation was performed as follows: sodium oleate was dissolved in phosphate buffer salt (PBS) to produce a 50 mmol L^−1^ stock solution using a shocking water bath at 55 °C, and then dropped into PBS containing 10% FBS for a 5 mmol L^−1^ working solution. The solution was then filtered through the 0.2 μm to remove bacteria in the solution and cryopreserved at 4 °C.

Preparation of COS I solution was performed as follows: COS I was dissolved in PBS to produce a 100 mg ml^−1^ stock solution, and then dropped into PBS containing 10% fetal bovine serum to produce a 10 mg ml^−1^ working solution. The solution was then filtered to remove bacteria in the solution and cryopreserved at 4 °C.

Preparation of the COS II solution was performed in the same manner as the COS I solution.

2.3. HepG2 cell culture {#s0025}
-----------------------

HepG2 cells were cultured using 13.5 g L^−1^ DMEM culture medium containing high glucose, 10% fetal bovine serum and double-antibiotic solution (penicillin 100 μmol·ml^−1^ and streptomycin 100 μg ml^−1^) in an incubator providing 5% CO~2~ at 37 °C. Subculture or subsequent trials were conducted when cell confluence reached 80--90% ([@b0085]).

2.4. HepG2 cell viability with the MTT method {#s0030}
---------------------------------------------

HepG2 cells were inoculated into 96-well culture plates with 1.0 × 10^4^ cells per well and cultured immediately. After 24 h incubation in an incubator containing 5% CO~2~ at 37 °C, the culture medium was replaced and injected with COS I and COS II at different concentrations. The final concentrations were 1.0 × 10^7^, 3.0 × 10^6^, 1.0 × 10^6^, 3.0 × 10^5^, 1.0 × 10^5^, 3.0 × 10^4^, 1.0 × 10^4^, and 3.0 × 10^3^ μg L^−1^, and were prepared alongside the no-induction and no-COS control groups. The final volumes of the six parallel wells in each group were 200 μl. After 24 h incubation in an incubator containing 5% CO~2~ at 37 °C, the experiment was conducted according to the following steps: 20 μl of 0.5 mg mL^−1^ MTT solution was injected into each well of 96-well culture plates and incubated for 4 h in the dark, culture medium was removed, 150 μl of DMSO was injected into each well of a 96-well culture plate, the plates were simultaneously shocked on the cell oscillator, the absorbance was read at 485 nm (OD~485~), and the cell survival rate (CSR) was calculated on the basis of OD~485~ to screen the suitable concentration range of the COS I and COS II ([@b0075]).$$\text{CSR} = (\text{Aa} - \text{A}0)/(\text{As} - \text{A}0) \times 100\%\text{.}$$

Aa, As and A0 represent the absorbance of the experiment group, no-COS control group and no-induction control group, respectively, in the formula.

2.5. Oil red O staining for HepG~2~ cells {#s0035}
-----------------------------------------

HepG2 cells were subcultured with 2.5 × 10^5^ cells per well in six-well culture dishes following 24 h incubation in the 37 °C incubator containing 5% CO~2~, and then were subsequently divided into nine groups (with six parallel wells in each group) as the blank control group, model group, berberine (Ber) control group due to its prevention of lipid accumulation in vitro and in vivo demonstrated in many studies ([@b0135], [@b0035]), and COS I and COS II groups with high (3.0 × 10^5^ μg L^−1^), middle (1.0 × 10^5^ μg L^−1^) and low (3.0 × 10^4^ μg L^−1^) concentrations, respectively. The ingredients in each group are shown as follows:Blank control group: high glucose DMEM culture medium containing 10% FBS.Model group: high glucose DMEM culture medium containing 10% FBS and oleic acid with a final concentration of 0.2 mmol L^−1^.Ber control group: high glucose DMEM culture medium containing 10% FBS, oleic acid and Ber with a final concentration of 0.2 mmol L^−1^ and 10 μmol L^−1^, respectively.COS I group: high glucose DMEM culture medium containing 10% FBS and oleic acid with a final concentration of 0.2 mmol L^−1^, COS I with final concentration of 3.0 × 10^5^ (high concentration), 1.0 × 10^5^ (middle concentration) and 3 × 10^4^ (low concentration) μg L^−1^.COS II group: high glucose DMEM culture medium containing 10% FBS and oleic acid with a final concentration of 0.2 mmol L^−1^, COS II with final concentration of 3.0 × 10^5^ (high concentration), 1.0 × 10^5^ (middle concentration), 3.0 × 10^4^ (low concentration) μg L^−1^.

After 24 h incubation, the culture medium was removed, and the experiment was conducted according to the following steps: 1 ml PBS was injected into each well and wells were then rinsed three times repeatedly, 500 μl of 4% paraformaldehyde was injected into each well for a 20 min fixation and then cleaned with 1 ml PBS three times repeatedly, 500 μl of Oil red O working solution was injected into each well and stained for 15 min in room temperature, 60% isopropanol was injected into each well for 1 min fixation and wells were cleaned with three rinses of isopropanol to produce a white transparent background, cell morphology and the distribution of lipid droplets were observed with the inverted microscope, and recorded as pictures, 500 μl of 60% isopropanol was injected into each well and incubated for 15 min at room temperature, after the extraction, 200 μl of leaching liquor was injected into 96-well culture plates, and absorbance of each well was determined at 485 nm ([@b0055]).

2.6. The determination of the intracellular TG {#s0040}
----------------------------------------------

HepG~2~ cells were inoculated into 24-well culture plates at 5.0 × 10^4^ cells per well and taken out after 24 h of incubation to set up the experimental groups as the blank control group, model group, Ber control group, and COS I and COS II groups with three different concentrations, 3.0 × 10^5^, 1.0 × 10^5^, and 3.0 × 10^4^ μg L^−1^, respectively, the ingredients in each group refer to 2.4. After 24 h incubation of the 24-well culture plates as described above, the culture solution was removed, they were cleaned with precooled PBS for three times and then blotted up, RIPA lysate (10^7^ cell ml^−1^) was injected in each group to produce sufficient lysis, the pyrolysis products of cells were scraped gently with cell scrapers and transferred into 1.5 ml Eppendorf (EP) tubes, respectively, they were shocked for 30 min and simultaneously centrifuged for 15 min (12,000 r min^−1^) at 4 °C, supernatant was collected, 10 μl supernatant in each EP tube was used for protein quantification by the BCA protein concentration determination kit method, the remaining supernatant was extracted by methanol-chloroform (V/V = 2:1), allowed to stand for 30 min, centrifuged for 15 min (12,000 r min^−1^) at 4 °C, the supernatant solution was removed and the bottom solution dried at 70 °C, 20 μl of PBS was injected for the dissolution of lipid ([@b0060]), and intracellular concentration of TG was determined according to the instructions of triglyceride determination kits.

2.7. Statistical analysis {#s0045}
-------------------------

The experimental data are represented as average value ± standard deviation (X ± S) and analyzed by SPSS 17.0 statistical software. The significance analysis is conducted by one-way ANOVA, with the statistical significance assigned to *P* \< 0.05.

3. Results {#s0050}
==========

3.1. Toxicological evaluation of COS I and COS II to HepG~2~ cells {#s0055}
------------------------------------------------------------------

COS I and COS II elicit some cytotoxicity at high concentrations. We explored the effects of COS I and COS II in different concentrations on normal HepG2 cell viability with the MTT method to choose a drug concentration characterized by the least toxicity to the cells. The results are shown in [Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"}. The cell viability decreases gradually with an increased concentration of COS I and COS II, suggesting that COS I and COS II in high concentration have some toxicity to HepG2 cells. COS I and COS II have the least toxicity to HepG2 cells at concentrations less than 3.0 × 10^5^ μg L^−1^. At this concentration, the cell viability is more than 90%, indicating that the concentration of COS I and COS II should be less than 3.0 × 10^5^ μg L^−1^ (The high, middle and low concentrations of COS I and COS II are 3.0 × 10^5^ μg L^−1^, 1.0 × 10^5^ μg L^−1^ and 3.0 × 10^4^ μg L^−1^, respectively).

3.2. HepG~2~ cell morphology and oil red O staining {#s0060}
---------------------------------------------------

The results of oil red O staining for HepG2 cellular morphology by the inverted microscope are displayed in [Fig. 3](#f0015){ref-type="fig"}, and HepG2 cells in the induced group contain a large number of red lipid droplets fused to each other, indicating that the HepG2 cell lipid accumulation model is established successfully. HepG2 red lipid droplets show a dose-dependent trend that is characterized by decreasing number, decreasing volume and shallow color. Compared with the induced group, the COS I and COS II middle and low concentration groups show obviously improved lipid accumulation and alleviated lipid fusion in the HepG2 cells. The lipid characteristics of the middle groups are comparable to those of the Ber positive group. The COS I and COS II high concentration groups show the effects described above even more obviously.

3.3. The effects of COS I and COS II in different concentrations on the HepG~2~ lipid accumulation model {#s0065}
--------------------------------------------------------------------------------------------------------

The absorbances for HepG2 cells in each group are shown below ([Fig. 4](#f0020){ref-type="fig"}) after the process of oil red O staining and extraction with isopropanol. It is observed that there is a significantly increasing lipid accumulation in HepG2 cells in the model group compared with blank group (*P* \< 0.001). Therefore, the effects of COS I and COS II in the high and middle concentration groups on the reduction in lipid accumulation are comparable to those of the Ber-positive control group.

3.4. The effects of COS I and COS II in different concentration on the content of TG in HepG~2~ lipid accumulation models {#s0070}
-------------------------------------------------------------------------------------------------------------------------

We observed the effects of COS I and COS II in the high, middle and low concentration groups (which are less toxic to HepG2 cells) on the content of TG in the HepG2 lipid accumulation model ([Figure 3](#f0015){ref-type="fig"}, [Figure 5](#f0025){ref-type="fig"}).

There is a significantly increasing content of TG in the model group compared with the blank control group (*P* \< 0.001), suggesting that the lipid accumulation model in HepG2 cells is established successfully. Compared with model groups, COS II in the high and middle concentrations and COS I in the high concentrations extremely decrease the TG content (*P* \< 0.001). An extremely significant difference exists between COS I at the middle concentration and the model group (*P* \< 0.01) and between the COS I, the COS II and the model groups. Notably, the decrease in TG accumulation is linearly correlated with an increasing concentration of COS I and COS II in the range from 3.0 × 10^4^ to 3.0 × 10^5^ μg L^−1^. Furthermore, the two COS have the strongest suppressive effects on TG content in HepG2 cells at 1.0 × 10^5^ μg L^−1^.

4. Conclusion and discussion {#s0075}
============================

NAFLD has gradually become a widespread and serious disease since the first official report of NAFLD in 1958, and the average incidence of NAFLD is approximately 20%, with a yearly increase. As the leading cause of hepatic dysfunction worldwide, the typical characteristic of NAFLD is intracellular lipid accumulation in hepatocytes ([@b0090]). The main lipid accumulating in liver of NAFLD patients is TG, and its accumulation results from an imbalance between its synthesis and transformation ([@b0105], [@b0100]). Genetic factors combined with the external environment and metabolic stress result in the pathogenesis of NAFLD, and the overwhelming theory for the molecular mechanism of NAFLD is the 'two-hit theory' as shown in a recent study ([@b0090], [@b0105], [@b0100]). The 'first' hit of the 'two-hit theory' is the lipid accumulation in the liver. Fatty degeneration of hepatocytes is more susceptible to 'second' hit (oxidative stress, etc) than normal one, which further promote the generation of inflammation that is the development of NAFLD. Based on this theory, the 'first' hit becomes an important target for prevention and treatment of NAFLD. Considering from this target, the experiment simulates lipid accumulation in hepatic cells, and then investigates the effect of drugs on the lipid accumulation model, which aims to screen the active substances in the prevention and treatment of NAFLD.

HepG2 cells have been successfully used for the establishment of a fatty liver cell model and because of their stable cell characteristics such as ease of cultivation, these cells can be used to screen for preventive and therapeutic drugs and to explore fatty liver pathogenesis ([@b0055], [@b0060]). Long-chain fatty acids can form into lipid droplets in cells, which lead to lipid accumulation ([@b0080]). As the foremost component of long-chain free fatty acids, oleic acid can be selected for the establishment of a lipid accumulation model in hepatocytes, which relates to the pathophysiological process of NAFLD ([@b0120], [@b0015]). The establishment of a hepatocyte lipid accumulation model can be achieved through induction by 1 mmol L^−1^ oleic acid for 24 h in HepG2 cells. After induction by oleic acid (0.1--2 mmol L^−1^) in a series of gradient concentrations in HepG2 cells, the level of intracellular lipid accumulation is positively correlated with oleic acid concentration.

For this study, we chose oleic acid as the 24 h continuous inducer for the establishment of lipid accumulating model, which can effectively simulate the pathological process of NAFLD, and we evaluated the roles of COS I and COS II in eliminating lipid accumulation in hepatocytes by detecting the conventional indexes of NAFLD such as the content of TG and lipid droplets in hepatocytes, simultaneously. The results show that the inhibition of TG accumulation by COS I and COS II in the high-dose groups is the most remarkable, with significant dose-dependent responses. Consequently, COS I and COS II present a potential medicinal value in the prevention and treatment of fatty liver. Nevertheless, the molecular mechanisms of inhibiting lipid accumulation in response to COS I and COS II have not been confirmed and will require further exploration in the future.
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![Effects of COS I on proliferation of HepG~2~ cells.](gr1){#f0005}

![Effects of COS II on proliferation of HepG~2~ cells.](gr2){#f0010}

![Oil red O staining maps of HepG~2~ cells (10 × 40). (A) Stained control group cells, (B) Stained induced group cells, (C) Stained 10 μmol L^−1^ berberine-positive cells, (D) Stained 3.0 × 10^5^ μg L^−1^ COS I-treated cells, (E) Stained 1.0 × 10^5^ μg L^−1^ COS I-treated cells, (F) Stained 3.0 × 10^4^ μg L^−1^ COS I-treated cells, (G) Stained 3.0 × 10^5^ μg L^−1^ COS II-treated cells, (H) Stained 1.0 × 10^5^ μg L^−1^ COS II-treated cells, (I) Stained 3.0 × 10^4^ μg L^−1^ COS II-treated cells.](gr3){#f0015}

![Effect of different experiments on lipid accumulation in HepG~2~ cells.](gr4){#f0020}

![Effect of COS I and COS II on the content of TG. Note: COS I and COS II groups with high (3.0 × 10^5^ μg L^−1^), middle (1.0 × 10^5^ μg L^−1^) and low (3.0 × 10^4^ μg L^−1^) concentrations, which also can be called IH, IM, IL and IIH, IIM, IIL for short respectively. ^\#\#\#^*P* \< 0.001, compared with the control group, ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001, compared with the model group.](gr5){#f0025}
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